The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme

Abstract

Background/aims:

Accurate information on harms arising from medical interventions is essential for assessing benefit–risk ratios. Since 2004, there has been an extension of the Consolidated Standards of Reporting Trials statement for reporting harms data in publications on randomized clinical trials. The objective of our study was to assess the quality of this reporting from academic randomized clinical trials on drugs.

Methods:

We searched for articles on randomized clinical trials funded between 2004 and 2008 by the “Programme Hospitalier de Recherche Clinique.” We included all published randomized clinical trials that assessed drugs. Harm-related data were extracted and compared with the Consolidated Standards of Reporting Trials Harms extension, and the space in the articles devoted to harms data was measured.

Results:

In total, 37 randomized clinical trials met the inclusion criteria. The median harm score was 9/18. In 73.0% of the randomized clinical trials, the reporting of adverse events was selective. Less than 50% of articles provided information on reasons for drug discontinuation that were related to adverse events. The score and the space allocated to harms were higher in antineoplastic and immunomodulating drugs randomized clinical trials, while the median proportion of the space in the results section allocated to harms was 16.8%. In 67.6% of the articles, the space allocated to the authors’ list and affiliations was greater than the space in the results section allocated to descriptions of harms. No significant improvement in the score or the space allocation was observed during the study period.

Conclusion:

Reporting of harms in French academic drug randomized clinical trials is suboptimal; moreover, this shortcoming is a critical barrier to evaluating the benefit–risk ratio of drug randomized clinical trials. Thus, the authors should be encouraged to adhere to the Consolidated Standards of Reporting Trials Harms extension.

Keywords

Consolidated Standards of Reporting Trials Harms extension randomized clinical trial academic research harms data adverse event reporting investigational drug

Get full access to this article

View all access options for this article.

References

Bent

Padula

Avins

. Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006; 144: 257–261.

Ioannidis

Mulrow

Goodman

. Adverse events: the more you search, the more you find. Ann Intern Med 2006; 144: 298–300.

Moher

Schulz

Altman

. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191–1194.

Ioannidis

Evans

Gotzsche

et al . Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141: 781–788.

Ioannidis

. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009; 169: 1737–1739.

Bagul

Kirkham

. The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting. Clin Exp Hypertens 2012; 34: 548–554.

De Vries

Van Roon

. Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. Arch Dis Child 2010; 95: 1023–1026.

Ethgen

Boutron

Steg

et al . Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials 2009; 10: 29.

Ioannidis

Lau

. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437–443.

10.

Capili

Anastasi

Geiger

. Adverse event reporting in acupuncture clinical trials focusing on pain. Clin J Pain 2010; 26: 43–48.

11.

Turner

Singh

Garritty

et al . An evaluation of the completeness of safety reporting in reports of complementary and alternative medicine trials. BMC Complement Altern Med 2011; 11: 67.

12.

Cornelius

Sauzet

Williams

et al . Adverse event reporting in randomised controlled trials of neuropathic pain: considerations for future practice. Pain 2012; 154: 213–220.

13.

Haidich

Birtsou

Dardavessis

et al . The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol 2010; 64: 124–135.

14.

Maggi

Griebeler

Dal Pizzol Tda

. Information on adverse events in randomised clinical trials assessing drug interventions published in four medical journals with high impact factors. Int J Risk Saf Med 2014; 26: 9–22.

15.

O’Day

Walton

Blennerhassett

et al . Reporting of harms by randomised controlled trials in ophthalmology. Br J Ophthalmol 2014; 98: 1003–1008.

16.

Smith

Chang

Pereira

et al . Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review. Pain 2012; 153: 2415–2421.

17.

Ioannidis

Contopoulos-Ioannidis

. Reporting of safety data from randomised trials. Lancet 1998; 352: 1752–1753.

18.

Badiaga

Foucault

Rogier

et al . The effect of a single dose of oral ivermectin on pruritus in the homeless. J Antimicrob Chemother 2008; 62: 404–409.

19.

Jabre

Combes

Lapostolle

et al . Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374: 293–300.

20.

Duval

van der Werf

Blanchon

et al . Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7: e1000362.

21.

Gerard

Azria

Gourgou-Bourgade

et al . Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638–1644.

22.

Preudhomme

Guilhot

Nicolini

et al . Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511–2521.

23.

Conroy

Desseigne

Ychou

et al . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.

24.

Ducloy-Bouthors

Jude

Duhamel

et al . High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011; 15: R117.

25.

Negrier

Gravis

Perol

et al . Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011; 12: 673–680.

26.

Pateron

Vicaut

Debuc

et al . Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med 2011; 57: 582–589.

27.

Attal

Lauwers-Cances

Marit

et al . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782–1791.

28.

Benamouzig

Uzzan

Deyra

et al . Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut 2012; 61: 255–261.

29.

Biondi

Schrappe

De Lorenzo

et al . Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936–945.

30.

Bocquet

Alaoui

Jais

et al . Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics 2012; 129: e269–e275.

31.

Moreau

Delval

Defebvre

et al . Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012; 11: 589–596.

32.

Prey

Ezzedine

Doussau

et al . Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012; 167: 1138–1144.

33.

Prunier

Biere

Gilard

et al . Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J 2012; 163: 200–207.

34.

Rozenberg

Chauveaud

Deruelle

et al . Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol 2012; 206: 206–209.

35.

Costedoat-Chalumeau

Galicier

Aumaitre

et al . Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS study). Ann Rheum Dis 2012; 72: 1786–1792.

36.

Gravis

Fizazi

Joly

et al . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149–158.

37.

Kodjikian

Souied

Mimoun

et al . Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013; 120: 2300–2309.

38.

Leger

Viala

Nicolas

et al . Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013; 80: 2217–2225.

39.

Mathurin

Louvet

Duhamel

et al . Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013; 310: 1033–1041.

40.

Ory-Magne

Corvol

Azulay

et al . Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology 2014; 82: 300–307.

41.

Papazian

Roch

Charles

et al . Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013; 310: 1692–1700.

42.

Devauchelle-Pensec

Mariette

Jousse-Joulin

et al . Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160: 233–242.

43.

Fizazi

Pagliaro

Laplanche

et al . Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014; 15: 1442–1450.

44.

Guillevin

Pagnoux

Karras

et al . Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771–1780.

45.

Gottenberg

Ravaud

Puechal

et al . Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312: 249–258.

46.

Haik

Marcon

Mallet

et al . Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13: 150–158.

47.

Malka

Cervera

Foulon

et al . Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15: 819–828.

48.

Schmitz

Fuchs

Closset

et al . Outpatient cervical ripening by nitric oxide donors for prolonged pregnancy: a randomized controlled trial. Obstet Gynecol 2014; 124: 1089–1097.

49.

Bernard

Dinh

Ghout

et al . Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet 2015; 385: 875–882.

50.

Milleron

Arnoult

Ropers

et al . Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2015; 36: 2160–2166.

51.

Pasquier

de Saint Martin

Bohec

et al . Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood 2015; 125: 2200–2205.

52.

Thevenot

Bureau

Oberti

et al . Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2014; 62: 822–830.

53.

Baud

Maury

Lebail

et al . Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 2016; 387: 1827–1836.

54.

Sautenet

Blancho

Buchler

et al . One-year results of the effects of Rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 2016; 100: 391–399.

55.

Maggi

Griebeler

Dal Pizzol Tda

. Adverse events reported in randomized clinical trials of drug therapies: the information is still insufficient. J Clin Epidemiol 2013; 66: 802–803.

56.

Peron

Maillet

Gan

et al . Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol 2013; 31: 3957–3963.

57.

Pitrou

Boutron

Ahmad

et al . Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169: 1756–1761.

58.

Shukralla

Tudur-Smith

Powell

et al . Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res 2011; 97: 20–29.

59.

Sivendran

Latif

McBride

et al . Adverse event reporting in cancer clinical trial publications. J Clin Oncol 2014; 32: 83–89.

60.

Ethgen

Boutron

Baron

et al . Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med 2005; 143: 20–25.

61.

Breau

Gaboury

Scales

et al . Reporting of harm in randomized controlled trials published in the urological literature. J Urol 2010; 183: 1693–1697.

62.

Carmichael

Nolan

Weston

et al . Assessment of the quality of harms reporting in non-randomised studies and randomised controlled studies of topiramate for the treatment of epilepsy using CONSORT criteria. Epilepsy Res 2015; 114: 106–113.

63.

Chowers

Gottesman

Leibovici

et al . Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. J Antimicrob Chemother 2009; 64: 239–250.

64.

Chen

Liu

Zhang

et al . A retrospective survey of quality of reporting on randomized controlled trials of metformin for polycystic ovary syndrome. Trials 2014; 15: 128.

65.

Hopewell

Dutton

et al . The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010; 340: c723.

66.

Shamseer

Hopewell

Altman

et al . Update on the endorsement of CONSORT by high impact factor journals: a survey of journal “instructions to authors” in 2014. Trials 2016; 17: 301.

67.

Dechartres

Charles

Hopewell

et al . Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed. J Clin Epidemiol 2011; 64: 136–144.